Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Nonseminomatous germ cell tumor × cabazitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 51 Neoplasm Metastasis 11 Neoplasms 8 Recurrence 7 Prostate Cancer Metastatic 6 Breast Neoplasms 5 Carcinoma, Transitional Cell 4 Stomach Neoplasms 3 Neoplastic Cells, Circulating 3 Metastatic Castration-resistant Prostate Cancer 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms, Castration-Resistant 2 Ovarian Neoplasms 2 Glioblastoma 2 Carcinoma, Squamous Cell 2 Carcinoma, Non-Small-Cell Lung 2 Thrombocytosis 1 Solid Cancer 1 Small Cell Lung Carcinoma 1 Prostate Cancer, Hereditary, 7 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Oligodendroglioma 1 Nonseminomatous germ cell tumor 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Etoposide 2 Drug Therapy 2 tremelimumab 1 trametinib 1 pembrolizumab 1 fludarabine phosphate 1 fludarabine 1 etoposide phosphate 1 durvalumab 1 dabrafenib 1 cabozantinib 1 cabazitaxel 1 Paclitaxel 1 Ifosfamide 1 Granulocyte Colony-Stimulating Factor 1 Cyclophosphamide 1 Cisplatin 1 Carboplatin 1 Brentuximab Vedotin 1 BEP protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02115165 2016-06-09

CABA-GCT

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Unknown

Nonseminomatous germ cell tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡